Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

Breakthrough Cancer Pain Clinical Trial

Official title:

Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05531422
• Other study ID #: ZK06
• Status: Completed
• Phase: Phase 2
• Start date: October 20, 2021
• Est. completion date: April 27, 2023

Study information

• Verified date: June 2024
• Source: Lee's Pharmaceutical Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase IIa dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough cancer pain.

Description:

Consenting patients who met inclusion and exclusion criteria were allowed to enter the study. The medication for background pain during screening were maintained until the end of the study. Each patient would be treated and observed for 6 episodes of targeted BTcP. Patients were randomly assigned to 1 of the 6 prespecified dose sequences which were established by a computer-generated schedule of active drug and placebo in a 4:2 ratio. All patients and personnel involved with the study (including investigators and investigation site personnel) were blinded to the medication codes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: April 27, 2023
• Est. primary completion date: March 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age of 18 years or above

2. Subjects must be diagnosed with cancer.

3. Subjects must experience persistent pain associated with cancer, and the pain score assessed by NRS should be <4 within 1week before screening.

4. In the past 7 days, the subject must experience an average of 1 to 4 episodes of breakthrough cancer pain per day,The breakthrough cancer pain score should be =4 assessed by NRS

5. ECOG status of 0 to 2.

6. Subjects must consent to take adequate contraception during the study and 1 months after the study. Women of childbearing potential must show negative in the pregnancy test before dosing.

7. The subject must be able to understand the requirements of the study and provide a written informed consent.

Exclusion Criteria:

1. History or suspected allergies to fentanyl.

2. HGB < 80 g/L, NEUT =1.0 × l09/L, PLT =50 × l09/L;ALT and AST higher than 3 times of ULN;total bilirubin and Cr higher than 1.5 times of ULN;PaO2 <95%;FEV1/FVC<70% and FEV1 accounted for less than 80% of the predicted value.

3. Any uncontrolled disease (e.g., severe mental, neurological, infectious, cardiovascular, respiratory and other systemic diseases).

4. Tumor infiltration to central nervous system.

5. Subjects are not able to slef evaluate pain intensity using NRS

6. Receive surgery in past 3 weeks

7. Treatment with any form of radiotherapy winth 1week prior to study entry that could alter pain or response to pain medication.

8. Taking monoamine oxidase inhibitors(MAOIs), CYP3A4 inhibitors or inducers within 14 days of the screening

9. Participated in other clinical trials in past 1months.

10. Pregnancy and breast-feeding women, women of childbearing age ready to conceive, and pregnancy test positive.

11. Other conditions that may affect the informed consent, compliance with the protocol, study results and safety of the subject.

Related Conditions & MeSH terms

• Breakthrough Cancer Pain
• Cancer Pain

Intervention

Drug:
• Inhaled fentanyl aerosol
Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
• Placebo
Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Lee's Pharmaceutical Limited

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SPID30	Weighted sum of pain intensity difference at post dose 30 minutes.Pain intensity at each breakthrough pain (BTP) episode at 0 ,4,8,12,16,20 and 30 minutes after first dose using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is "worst possible pain". PID30 is calculated as the difference in pain intensity from time 0 to 30 minutes. A positive value is a decrease (improvement) of the pain.SPID30=PID4*4+PID8*4+PID12*4+PID16*4+PID20*4+PID30*10	at each episode of breakthrough pain, 30 minutes after first dose of study drug.
Secondary	Pain intensity at 0, 4,8,12,16,20,30 and 60 minutes post-dose	Pain intensity at each breakthrough pain (BTP) episode at 0 ,4,8,12,16,20, 30 and 60 minutes after first dose using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is "worst possible pain".A positive value is a decrease (improvement) of the pain.	at each episode of breakthrough pain, 60 minutes after first dose of study drug.